Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Patient Voice 2026
Throughout Septembre Rouge 2026, Priothera SAS invited Carolina, an AML patient advocate, to share her story in a four-part video series.
From the shock of diagnosis and the journey through stem cell transplantation to life after transplant and her hopes for the future, Carolina speaks openly about what it means to live with AML — and about the challenges that remain after transplantation.
Her story gives a voice to many patients who are waiting for more effective maintenance treatments to help prevent relapse and improve long-term outcomes — and echoes Priothera’s commitment to addressing this unmet need.
Watch the four videos:
1. The day everything changed
2. The donor who gave me a second chance
3. Life after transplant
4. My wish for innovative maintenance treatment
Location, location, location: fighting hematological malignancies by trapping T cells in lymphoid tissue
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Priothera Enters Loan Agreement of €17.5 Million with the European Investment Bank
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer